Blog
RSS FeedPosted by Michael Wonder on 23 May 2019
TGA fees and charges: summary from 1 July 2019
23 May 2019 - The TGA is required to recover its costs for all activities that fall within the scope ...
Posted by Michael Wonder on 21 May 2019
South Africa's Aspen sells Australian prescription portfolio to Mylan
20 May 2019 - Aspen Pharmacare has said that Mylan had exercised an option to buy the South African drug ...
Posted by Michael Wonder on 16 May 2019
Sigma Healthcare leadership says it has received no worker reports of medicine mishandling
16 May 2019 - Sigma Healthcare's chief executive Mark Hooper has told investors that the company takes its obligations to ...
Posted by Michael Wonder on 15 May 2019
Sigma Healthcare to face investor questions over claims it mishandled prescription drugs
15 May 2019 - Pharmaceutical supplier Sigma Healthcare will face shareholder questions over claims that it failed to properly handle ...
Posted by Michael Wonder on 08 May 2019
Medicines Australia welcomes ALP R&D investment pledge
8 May 2019 - Medicines Australia welcomes today’s announcement from the Australian Labor Party to reform the Research and Development ...
Posted by Michael Wonder on 01 May 2019
Newly approved MS drug to offer relief to children
1 May 2019 - A wonder drug to treat children with multiple sclerosis has been approved for use in Australia. ...
Posted by Michael Wonder on 25 Apr 2019
Aytu BioScience announces submission of ZolpiMist for approval to Australian TGA
24 April 2019 - Australian TGA approval decision expected in early 2020. ...
Posted by Michael Wonder on 09 Apr 2019
International work-sharing initiative - abemaciclib (Verzenio)
9 April 2019 - Abemaciclib (Verzenio) is the second medicine to be registered on the Australian Register of Therapeutic Goods ...
Posted by Michael Wonder on 18 Mar 2019
New early breast cancer drug to reduce risk of recurrence or death approved for Australian women
18 March 2019 - Nerlynx (neratinib) now approved by the Therapeutic Goods Administration for Australian women. ...
Posted by Michael Wonder on 12 Mar 2019
Vertex receives approval for Symdeko (tezacaftor/ivacaftor and ivacaftor) in Australia, to treat the underlying cause of cystic fibrosis in people aged 12 and older with certain CFTR gene mutations
12 March 2019 - A new treatment option for patients with two copies of the F508del mutation, the most common mutation ...
Posted by Michael Wonder on 15 Feb 2019
Whether the TGA should publish that a prescription medicine is under evaluation
15 February 2019 - The TGA is seeking comments from interested parties on whether or not the TGA should in future ...
Posted by Michael Wonder on 16 Jan 2019
Sweet smell of success for patients taking the sugar pill
15 January 2019 - A placebo is anything that seems to offer a real medical treatment, but doesn’t. It could ...
Posted by Michael Wonder on 09 Jan 2019
New drug to halve heart patients' cholesterol levels
9 January 2019 - A second drug has been approved for use in Australia for patients with high cholesterol who ...
Posted by Michael Wonder on 12 Dec 2018
PharmaMar announces the approval of Aplidin in Australia for the treatment of multiple myeloma
11 December 2018 - PharmaMar has licensed Aplidin to its partner, STA, in Australia, New Zealand and several Southeast Asian countries. ...
Posted by Michael Wonder on 03 Dec 2018
Australia's first telehealth cancer drug trial
3 December 2018 - A partnership between north Queensland hospitals is bringing potentially life-saving cancer drug trials to rural patients. ...